金花企业(集团)股份有限公司 证券代码：600080 股票简称：金花股份 编号：临 2025-017 机构名称：信永中和会计师事务所（特殊普通合伙） 统一社会信用代码：91110101592354581W 2.人员信息 关于续聘会计师事务所的公告 一、拟聘任会计师事务所的基本情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （一）机构信息 拟续聘的会计师事务所名称：信永中和会计师事务所（特殊普通合伙） 金花企业（集团）股份有限公司（以下简称"公司"）于2025年4月23日召开 第十届董事会第十八次会议，审议并通过《关于公司续聘会计师事务所的议案》， 同意续聘信永中和会计师事务所（特殊普通合伙）（以下简称"信永中和"）为 公司2025年度财务报告及内部控制审计机构，并同意将该议案提交股东大会审 议。现将相关情况公告如下： 1.基本信息： 拟签字项目合伙人：翟晓敏女士，2002 年获得中国注册会计师资质，2002 年开始从事上市公司审计，2019 年开始在信永中和执业，2021 年开始为本公司 提供审计服 ...

金花企业（集团）股份有限公司 董事会审计委员会 对会计师事务所 2024 年度履行监督职责情况报告 根据《公司法》、《证券法》、《上市公司治理准则》、《国有企业、上市 公司选聘会计师事务所管理办法》、《上海证券交易所上市公司自律监管指引第 1 号—规范运作》等法律法规以及金花企业（集团）股份有限公司（以下简称"公 司"）的《公司章程》、《董事会审计委员会工作细则》等规章制度，作为公司 董事会审计委员会委员，本着勤勉尽责的原则，恪尽职守，认真履行审计监督职 责。现将董事会审计委员会对会计师事务所 2024 年度履职评估及监督职责情况 汇报如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 信永中和会计师事务所（特殊普通合伙）（以下简称"信永中和"或"会计 师事务所"）成立于 2012 年 3 月 2 日，注册地址为北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层，首席合伙人为谭小青先生。截止 2024 年 12 月 31 日，信 永中和合伙人（股东）259 人，注册会计师 1780 人。签署过证券服务业务审计 报告的注册会计师人数超过 700 人。 按照审计业务约定书，遵循《中 ...

金花企业(集团)股份有限公司 关于 2024 年度利润分配方案的公告 证券代码：600080 股票简称：金花股份 编号：临 2025-014 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 每股分配比例：每10股派发现金红利0.3元（含税）。 本次利润分配金花企业（集团）股份有限公司（以下简称"公司"）实 施权益分派股权登记日登记的总股本扣除公司回购专用证券账户的股份数为基 数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本扣除公司回购专用证券账户 中股份数发生变动的，公司拟维持每股分配比例不变，相应调整分配总额，并将 在相关公告中披露。 本次利润分配预案不触及《上海证券交易所股票上市规则（2024年4月修 订）》第9.8.1条第一款第（八）项规定的可能被实施其他风险警示的情形。 本次利润分配预案已经公司第十届董事会第十八次会议、第十届监事会 第十一次会议审议通过，尚需提交公司2024年年度股东大会审议。 一、利润分配方案内容 （一）利润分配方案的具体内容 经信永中和会计师事 ...

金花企业（集团）股份有限公司董事会 关于 2024 年度带强调事项段的无保留意见的审计报告和带强调 事项段的无保留意见的内部控制审计意见涉及事项的专项说明 信永中和会计师事务所（特殊普通合伙）（以下简称"信永中和"或"审计 机构"）受金花企业（集团）股份有限公司（以下简称"公司"或"金花股份"） 的委托，对公司 2024 年度财务报告和内部控制进行了审计，并出具了带强调事 项段的无保留意见的审计报告（XYZH/2025XAAA5B0247）和带强调事项段的无保 留意见的内部控制审计报告（XYZH/2025XAAA5B0246）。根据中国证券监督管理委 员会《公开发行证券的公司信息披露编报规则第 14 号—非标准审计意见及其涉 及事项的处理》、《上海证券交易所上市公司自律监管指引第 1 号—规范运作》等 相关规定，公司董事会就涉及事项专项说明如下： 一、强调事项段涉及事项的基本情况 （一）信永中和带强调事项段的无保留意见财务报告审计报告涉及事项如下 （1）金花股份于 2025 年 1 月 24 日与志丹县塞尚高原油气勘探开发有限公 司签订燃气供销合同，并预付采购款 1,980.00 万元，其商业合理性存在重大不 ...

证券代码：600080 证券简称：金花股份 公告编号：2025-020 金花企业（集团）股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 15 日 13 点 30 分 召开地点：陕西省西安市高新三路财富中心三期南座 40 层会议室 股东大会召开日期：2025年5月15日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 15 日 至2025 年 5 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥107,322,617.51, a decrease of 7.31% compared to ¥115,789,270.68 in the same period last year[4] - Net profit attributable to shareholders was ¥1,215,305.87, reflecting a significant decline of 94.93% from ¥23,962,427.14 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 151.79% to ¥10,674,621.80 from ¥4,239,492.97 in the previous year[4] - Basic and diluted earnings per share were both ¥0.0034, down 94.75% from ¥0.0648 in the previous year[4] - The company reported a significant decrease in net profit primarily due to the absence of investment income from the disposal of subsidiaries recognized in the previous year[4] - Total revenue for Q1 2025 was CNY 107,322,617.51, a decrease from CNY 115,789,270.68 in Q1 2024[17] - Net profit for Q1 2025 was CNY 1,213,505.40, compared to CNY 23,962,427.14 in Q1 2024, indicating a significant decline[18] - Operating profit for Q1 2025 was CNY 686,761.56, a decrease from CNY 28,270,193.02 in Q1 2024[18] - Total comprehensive income for the period amounted to CNY 1,213,505.40, with the total attributable to the parent company being CNY 1,215,305.87[19] - Basic and diluted earnings per share for the period were CNY 0.0034, compared to CNY 0.0648 in the previous period[19] Cash Flow and Liquidity - The net cash flow from operating activities was -¥121,368,520.52, worsening from -¥49,212,848.23 in the same period last year[4] - Cash inflows from operating activities totaled CNY 102,614,406.29, a decrease from CNY 139,272,969.60 in the same quarter last year[21] - Cash outflows from operating activities amounted to CNY 223,982,926.81, compared to CNY 188,485,817.83 in the previous year[21] - Cash inflows from investing activities were CNY 290,856,141.73, down from CNY 452,758,287.53 in the prior year[22] - Net cash flow from investing activities was CNY -132,574,698.96, compared to CNY -100,782,751.69 in the previous year[22] - Cash inflows from financing activities totaled CNY 136,307,923.94, a decrease from CNY 206,522,689.02 in the same quarter last year[23] - Net cash flow from financing activities was CNY 34,473,274.97, improving from CNY -106,746,213.65 year-over-year[23] - The ending cash and cash equivalents balance was CNY 118,450,647.88, down from CNY 362,990,968.10 in the previous year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,991,845,145.12, an increase of 1.00% from ¥1,972,071,163.91 at the end of the previous year[5] - Total current assets decreased to CNY 760,423,456.14 from CNY 782,365,271.63 year-over-year[12] - Total non-current assets increased to CNY 1,231,421,688.98 from CNY 1,189,705,892.28 year-over-year[13] - Total liabilities rose to CNY 431,147,881.41 from CNY 412,587,405.60 year-over-year[14] - Shareholders' equity totaled CNY 1,560,697,263.71, slightly up from CNY 1,559,483,758.31 year-over-year[14] - Cash and cash equivalents decreased to CNY 167,711,032.80 from CNY 347,680,977.31 year-over-year, indicating liquidity challenges[12] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,108, with the largest shareholder holding 19.63% of the shares[8] Research and Development - Research and development expenses increased to CNY 11,691,377.11 in Q1 2025 from CNY 2,329,533.04 in Q1 2024, reflecting a focus on innovation[18] Government Support - The company received government subsidies amounting to ¥148,787.91 during the period, while non-operating losses totaled -¥9,459,315.93 after tax effects[6] Return on Equity - The weighted average return on equity decreased to 0.0778%, down 1.4289 percentage points from 1.5068% in the previous year[4]

Financial Performance - The net profit attributable to the parent company for 2024 is CNY 68,896,722.55, with a statutory reserve of CNY 6,889,672.26, resulting in a distributable profit of CNY 563,436,934.21 for shareholders[5]. - The company's total revenue for 2024 is CNY 585,461,786.23, representing a 3.55% increase compared to CNY 565,403,410.11 in 2023[21]. - The net profit attributable to shareholders in 2024 shows a significant recovery, reaching CNY 74,611,329.88, compared to a loss of CNY 42,890,580.25 in 2023[21]. - The basic earnings per share for 2024 is CNY 0.2088, a substantial improvement from a loss of CNY 0.1149 in 2023[22]. - The net profit after deducting non-recurring gains and losses for 2024 is CNY 13,774,886.74, a 358.44% increase from CNY 3,004,719.15 in 2023[21]. - The company reported a significant decrease in hotel business revenue by 96.01% compared to the previous year[119]. - The total amount of cash dividends, including share repurchases, is 160,082,572.65 RMB, exceeding the net profit by 214.56%[191]. Assets and Cash Flow - The company's total assets decreased by 6.47% to CNY 1,972,071,163.91 at the end of 2024, down from CNY 2,108,551,141.95 in 2023[21]. - The net cash flow from operating activities for 2024 is CNY 10,858,725.20, reflecting an 82.07% decline from CNY 60,548,425.38 in 2023[21]. - Cash and cash equivalents decreased by 43.96% to CNY 347.68 million, down from CNY 620.45 million in the previous period[78]. - The company faced a 239.59% decline in net cash flow from investing activities, resulting in -192,303,593.87 for the period[76]. Research and Development - The company is actively enhancing its research and development capabilities by integrating resources and collaborating with external research institutions[32]. - Research and development expenses increased by 91.94% to CNY 28.96 million, indicating a strong commitment to innovation[54]. - The company is focusing on high-quality innovation development in the pharmaceutical industry, with policies aimed at drug innovation and rare disease drug research[84]. - The company is actively engaged in R&D, focusing on secondary development of existing products and new product development, enhancing its core competitiveness[108]. Market and Product Strategy - The company is focusing on innovation and market positioning to enhance core competitiveness amid increasing industry competition[29]. - The company has established a nationwide marketing network, leveraging academic promotion and collaboration with key opinion leaders to enhance product visibility and application[49]. - The company focuses on the development of core products in orthopedics, immunology, and pediatrics, with its leading product, Jintian Ge Capsule, recognized for its clinical efficacy and quality[48]. - The revenue from pharmaceutical industrial products was CNY 584.81 million, up 4.43% year-on-year, primarily driven by a 9.11% increase in orthopedic product revenue[52]. Corporate Governance - The company has established a comprehensive corporate governance structure in compliance with relevant laws and regulations, ensuring clear responsibilities among its governing bodies[147]. - The board of directors operates efficiently with committees for strategy, nomination, audit, and compensation, adhering to legal requirements[148]. - The company has implemented strict insider information management practices, maintaining fairness and transparency in information disclosure[149]. - The company has not reported any major issues related to corporate governance during the reporting period[196]. Regulatory Environment - The pharmaceutical industry is undergoing significant transformation, driven by policy changes and increasing competition, necessitating a shift towards innovation and refined operations[36]. - The introduction of 91 new drugs in the national medical insurance drug list for 2024 includes 38 innovative drugs, significantly improving coverage for cancer, chronic diseases, and rare diseases[86]. - The State Medical Insurance Bureau aims to eliminate unfair pricing of generic drugs across provinces by March 2024, promoting a transparent pricing system[87]. Employee Management and Training - The total number of employees at the parent company and major subsidiaries is 588, with 582 at the parent company and 6 at subsidiaries[173]. - The company has a training plan for 2024 aimed at enhancing management capabilities and quality management systems[175]. - The training program includes operational skills training, safety drills, and legal regulations awareness to ensure compliance and safety[176]. - The company has maintained a consistent training and evaluation process for employees, ensuring compliance with regulations and enhancing operational efficiency[186]. Future Outlook - The company plans to continue increasing R&D investment to promote high-quality business development in the pharmaceutical and health industry[112]. - Future guidance suggests a continued growth trajectory, with expectations for increased user engagement and revenue growth[154]. - The company aims to improve production quality management and optimize procurement mechanisms to reduce costs and ensure market supply[138].

证券代码：600080 股票简称：金花股份 编号：临 2025-013 金花企业（集团）股份有限公司 第十届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 金花企业（集团）股份有限公司第十届监事会第十一次会议通知于 2025 年 4 月 14 日以电子邮件及微信方式发出，会议于 2025 年 4 月 23 日以现场方式在公 司会议室召开。应出席监事 3 人,实际出席 3 人，会议由监事会主席马斌先生主 持，本次会议的召集召开符合《公司法》和《公司章程》的有关规定，经讨论表 决，通过如下决议： 一、通过《公司 2024 年度监事会工作报告》 表决情况：同意票 3 票，反对票 0 票，弃权票 0 票。 本议案尚须提请股东大会审议批准。 二、通过《公司 2024 年年度报告及摘要》 表决情况：同意票 3 票，反对票 0 票，弃权票 0 票。 本议案尚须提请股东大会审议批准。 三、通过《关于公司 2024 年年度报告的审核意见》 表决情况：同意票 3 票，反对票 0 票，弃权票 0 票。 根据《公司法 ...

金花企业（集团）股份有限公司 第十届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 金花企业（集团）股份有限公司（以下简称"公司"）第十届董事会第十八次会 议通知于 2025 年 4 月 14 日以电子邮件及微信方式发出，会议于 2025 年 4 月 23 日以 现场和通讯结合的方式在公司会议室召开。应出席董事 7 人，实际出席董事 7 人，其 中现场出席董事 6 人，独立董事赵舸女士以通讯方式参会。会议由董事长邢雅江先生 主持，公司监事及高管人员列席会议。本次会议符合《公司法》和《公司章程》的有 关规定，经讨论表决，会议通过如下决议： 二、董事会会议审议情况 证券代码：600080 股票简称：金花股份 编号：临 2025-012 （一）通过《公司 2024 年年度报告》及《2024 年年度报告摘要》 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票。 本议案已经第十届董事会审计委员会第十四次会议审议通过。 《2024 年年度报告摘要》详见上海证券报及上海证券交 ...

金花企业（集团）股份有限公司 2024 年度 审计报告 | 索引 | | 页码 | | --- | --- | --- | | 审计报告 | | 1-5 | | 公司财务报表 | | | | — | 合并资产负债表 | 1-2 | | — | 母公司资产负债表 | 3-4 | | — | 合并利润表 | 5 | | — | 母公司利润表 | 6 | | — | 合并现金流量表 | 7 | | — | 母公司现金流量表 | 8 | | — | 合并股东权益变动表 | 9-10 | | — | 母公司股东权益变动表 | 11-12 | | — | 财务报表附注 | 13-103 | 审计报告 XYZH/2025XAAA5B0247 金花企业（集团）股份有限公司 金花企业（集团）股份有限公司全体股东： 一、 审计意见 我们审计了金花企业（集团）股份有限公司（以下简称金花股份公司）财务报表， 包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、 合并及母公司现金流量表、合并及母公司股东权益变动表，以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计 ...